Coming Soon
Candidal Vulvovaginitis, also known as a Yeast Infection or Vulvovaginal Candidiasis, is a common fungal infection. This page provides information for healthcare professionals on diagnosis, treatment, and clinical documentation of Candidal Vulvovaginitis, including relevant medical coding terms for accurate billing and record keeping. Learn about symptoms, diagnostic criteria, and best practices for managing this condition in a clinical setting.
Also known as
Candidal vulvovaginitis
Yeast infection of the vulva and vagina.
Candidiasis of other urogenital sites
Yeast infection of urinary or genital areas, excluding vulva/vagina.
Other specified candidal infections
Candidiasis (yeast infection) at a specific site not listed elsewhere.
Candidiasis, unspecified
Yeast infection without a specified location.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the candidal infection confirmed?
When to use each related code
| Description |
|---|
| Yeast infection of the vulva and vagina. |
| Bacterial vaginosis, not candida. |
| Inflammation of the vagina, not from infection. |
Coding for unspecified candidiasis (B37.9) when clinical details support a more specific code like B37.3 (Candidal vulvovaginitis).
Coding candidal vulvovaginitis based on symptoms alone without confirmatory diagnostic testing, leading to potential overcoding and inaccurate data.
Failing to capture and code related conditions like diabetes, which can predispose to candidal vulvovaginitis, impacting risk adjustment and quality metrics.
Q: What are the most effective diagnostic approaches for recurrent vulvovaginal candidiasis in non-pregnant patients, considering both clinical presentation and laboratory confirmation?
A: Recurrent vulvovaginal candidiasis (RVVC), defined as four or more episodes per year, presents a diagnostic challenge. Clinical presentation alone isn't sufficient due to overlapping symptoms with other vulvovaginal conditions. While vaginal pH and wet mount microscopy with potassium hydroxide (KOH) are commonly used, their sensitivity for non-albicans species is limited. Culture on Sabouraud's dextrose agar remains the gold standard for species identification, crucial for targeted therapy and management of RVVC. Molecular methods, such as PCR, offer increased sensitivity and specificity, especially for detecting non-albicans species and mixed infections. A comprehensive approach, considering both clinical signs and symptoms alongside confirmatory laboratory tests, is vital for accurately diagnosing RVVC. Explore how antifungal susceptibility testing can further personalize treatment strategies for recurrent infections.
Q: How do I differentiate vulvovaginal candidiasis from bacterial vaginosis and other common vaginal infections in a clinical setting, and what specific diagnostic tests should be prioritized?
A: Differentiating vulvovaginal candidiasis (VVC) from bacterial vaginosis (BV) and other vaginal infections requires a systematic approach. While VVC typically presents with thick, white discharge and pruritus, BV often features a thin, homogenous, grayish discharge with a characteristic fishy odor. Trichomoniasis may present with frothy discharge and vulvar irritation. Microscopic examination with KOH can reveal fungal elements in VVC, while a wet mount for BV may show clue cells and a pH above 4.5. Amsel criteria are helpful for diagnosing BV, while nucleic acid amplification tests (NAATs) are highly sensitive and specific for Trichomonas vaginalis. Consider implementing a diagnostic algorithm that incorporates clinical findings, microscopic evaluation, and point-of-care or laboratory testing for accurate differentiation and appropriate treatment selection. Learn more about the role of vaginal pH and its interpretation in various vaginal infections.
Patient presents with complaints consistent with vulvovaginal candidiasis, also known as a yeast infection or candidal vulvovaginitis. Symptoms include vulvar pruritus, burning, and thick, white, cottage cheese-like vaginal discharge. Patient reports no fever or chills. Erythema and edema of the vulva and vagina were noted upon examination. A wet mount preparation revealed pseudohyphae and budding yeast, confirming the diagnosis of candidal vulvovaginitis. Differential diagnoses considered included bacterial vaginosis and trichomoniasis. Patient denies recent antibiotic use or other predisposing factors. Treatment plan includes fluconazole 150mg PO single dose. Patient education provided on proper hygiene practices and preventative measures for recurrent yeast infections. Follow-up recommended if symptoms do not resolve within one week. ICD-10 code B37.3 assigned.